KalVista Pharmaceuticals indicated that Merck had allowed the option deal between the companies for the intravitreal diabetic macular edema (IDME) drug KVD001 and future DME molecules to expire.
https://www.pharmalive.com/wp-content/uploads/2020/02/KalVista-Merck-DME-Deal-BioSpace-2-11-20.jpeg350625BioSpacehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBioSpace2020-02-11 11:59:172020-02-12 14:20:08KalVista Plans to Continue Work on Diabetic Macular Edema After Merck Walks Away from Deal